These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38700719)

  • 1. SGLT2 inhibitor as a potential therapeutic approach in hyperthyroidism-induced cardiopulmonary injury in rats.
    Bastawy N; El-Mosallamy AEMK; Aljuaydi SH; AbuBakr HO; Rasheed RA; Sadek AS; Khattab RT; Abualyamin WB; Abdelaal SE; Boushra AF
    Pflugers Arch; 2024 Jul; 476(7):1125-1143. PubMed ID: 38700719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis.
    Hassan HA; Nageeb MM; Mohammed HO; Samy W; Fawzy A; Afifi R; Abbas NAT
    Toxicol Appl Pharmacol; 2024 Aug; 489():116991. PubMed ID: 38871090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
    Lin YW; Chen CY; Shih JY; Cheng BC; Chang CP; Lin MT; Ho CH; Chen ZC; Fisch S; Chang WT
    J Am Heart Assoc; 2021 Apr; 10(7):e019274. PubMed ID: 33749310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
    Hodrea J; Saeed A; Molnar A; Fintha A; Barczi A; Wagner LJ; Szabo AJ; Fekete A; Balogh DB
    PLoS One; 2022; 17(2):e0263285. PubMed ID: 35176041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-
    Liu L; Luo H; Liang Y; Tang J; Shu Y
    Comput Math Methods Med; 2022; 2022():3293054. PubMed ID: 35096128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels.
    Liu DD; Liu XL; Zheng TF; Li X; Zhao YC; Pan JC; Yuan C; Wang QQ; Zhang M
    Eur J Pharmacol; 2024 Oct; 981():176875. PubMed ID: 39121982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
    El-Shafey M; El-Agawy MSE; Eldosoky M; Ebrahim HA; Elsherbini DMA; El-Sherbiny M; Asseri SM; Elsherbiny NM
    Front Endocrinol (Lausanne); 2022; 13():862394. PubMed ID: 35370937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
    Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
    J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.
    Lin K; Yang N; Luo W; Qian JF; Zhu WW; Ye SJ; Yuan CX; Xu DY; Liang G; Huang WJ; Shan PR
    Acta Pharmacol Sin; 2022 Oct; 43(10):2624-2635. PubMed ID: 35217813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
    Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
    Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
    Rodriguez D; Kapoor S; Edenhofer I; Segerer S; Riwanto M; Kipar A; Yang M; Mei C; Wüthrich RP
    Kidney Blood Press Res; 2015; 40(6):638-47. PubMed ID: 26698317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease.
    Martínez-Rojas MÁ; Balcázar H; González-Soria I; González-Rivera JM; Rodríguez-Vergara ME; Velazquez-Villegas LA; León-Contreras JC; Pérez-Villalva R; Correa F; Rosetti F; Bobadilla NA
    JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38516890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.